Wells Fargo & Company MN increased its position in Calithera Biosciences, Inc. (NASDAQ:CALA) by 705.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,832 shares of the biotechnology company’s stock after acquiring an additional 23,500 shares during the period. Wells Fargo & Company MN owned approximately 0.08% of Calithera Biosciences worth $399,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of the stock. Bank of New York Mellon Corp grew its position in Calithera Biosciences by 17.5% during the 1st quarter. Bank of New York Mellon Corp now owns 32,688 shares of the biotechnology company’s stock worth $377,000 after purchasing an additional 4,863 shares during the period. FMR LLC grew its position in Calithera Biosciences by 278.2% during the 1st quarter. FMR LLC now owns 1,462,190 shares of the biotechnology company’s stock worth $16,888,000 after purchasing an additional 1,075,592 shares during the period. Vanguard Group Inc. grew its position in Calithera Biosciences by 99.8% during the 1st quarter. Vanguard Group Inc. now owns 925,015 shares of the biotechnology company’s stock worth $10,684,000 after purchasing an additional 462,137 shares during the period. Geode Capital Management LLC grew its position in Calithera Biosciences by 61.6% during the 1st quarter. Geode Capital Management LLC now owns 107,169 shares of the biotechnology company’s stock worth $1,236,000 after purchasing an additional 40,841 shares during the period. Finally, Morgan Stanley grew its position in Calithera Biosciences by 1,053.6% during the 1st quarter. Morgan Stanley now owns 98,161 shares of the biotechnology company’s stock worth $1,133,000 after purchasing an additional 89,652 shares during the period. Institutional investors own 71.88% of the company’s stock.

WARNING: “Calithera Biosciences, Inc. (CALA) Shares Bought by Wells Fargo & Company MN” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.thecerbatgem.com/2017/11/15/calithera-biosciences-inc-cala-shares-bought-by-wells-fargo-company-mn.html.

CALA has been the topic of several analyst reports. BidaskClub downgraded Calithera Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. William Blair assumed coverage on Calithera Biosciences in a research report on Thursday, October 5th. They set an “outperform” rating on the stock. Finally, Zacks Investment Research upgraded Calithera Biosciences from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a research report on Monday, November 6th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. Calithera Biosciences currently has a consensus rating of “Buy” and an average target price of $15.17.

Shares of Calithera Biosciences, Inc. (NASDAQ:CALA) opened at $9.40 on Wednesday. Calithera Biosciences, Inc. has a 12-month low of $2.90 and a 12-month high of $20.05.

Calithera Biosciences (NASDAQ:CALA) last posted its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.17) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.06. The business had revenue of $7.20 million for the quarter, compared to analyst estimates of $6.02 million. sell-side analysts expect that Calithera Biosciences, Inc. will post -0.77 EPS for the current year.

In related news, major shareholder Adage Capital Partners Gp, L.L sold 576,000 shares of the firm’s stock in a transaction dated Thursday, September 28th. The shares were sold at an average price of $15.64, for a total value of $9,008,640.00. The sale was disclosed in a document filed with the SEC, which is available through this link. 16.30% of the stock is owned by company insiders.

Calithera Biosciences Company Profile

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Want to see what other hedge funds are holding CALA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Calithera Biosciences, Inc. (NASDAQ:CALA).

Institutional Ownership by Quarter for Calithera Biosciences (NASDAQ:CALA)

Receive News & Stock Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related stocks with our FREE daily email newsletter.